Skip to main content

Comprehensive Hematology Oncology

Advancing Cancer Care Through Clinical Research

At Comprehensive Hematology Oncology, our research team brings clinical trials closer to home, providing patients with access to promising therapies and carefully designed research studies alongside comprehensive cancer care.

Comprehensive Hematology Oncology Logo

Advancing Cancer Care Through Clinical Trials

Clinical trials play an important role in advancing the field of hematology and oncology. These research studies evaluate new approaches to screening, diagnosis, prevention, and treatment while helping physicians and researchers develop better options for patients.

At Comprehensive Hematology Oncology, we are proud to offer clinical research opportunities close to home. Our clinical trials give eligible patients access to approved and investigational therapies while contributing to the development of new standards of care.

Each clinical trial follows a carefully designed protocol with specific eligibility requirements and safety measures. Depending on the study, clinical trials may progress through several phases:

Phase I: Evaluates safety, determines appropriate dosage, and studies how the body responds to a new treatment.

Phase II: Continues to evaluate safety while examining whether the treatment may be effective against a specific cancer or condition.

Phase III: Compares a new treatment or treatment approach with the current standard of care in a larger group of patients.

Phase IV: Conducted after a treatment has been approved to continue monitoring its long-term safety and effectiveness.

Clinical trials are conducted according to established protocols designed to protect participants and ensure that research is carried out consistently. Before a study begins, the protocol is reviewed by an Institutional Review Board (IRB) to help protect the rights, safety, and well-being of participants.

Cancer treatment tampa fl
hematologist in Tampa, FL

“From the moment I walked through the door, I felt cared for and supported. The entire team was kind, compassionate, and professional. I truly felt that I was in good hands.”

COMPREHENSIVE HEMATOLOGY ONCOLOGY PATIENT

Connect With Our Clinical Research Team

Have questions about clinical trials, eligibility, or currently enrolling studies? Our Clinical Research Team is here to provide more information and help you understand your options.

Trial Name Category View More
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01) FIRST LINE LUNG CANCER View More
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients FIRST LINE LUNG CANCER View More
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC FIRST LINE LUNG CANCER View More
Study of Olomorasib (LY3537982) in Combination with Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02) FIRST LINE LUNG CANCER View More
A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer SECOND-LINE LUNG CANCER View More
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA) SECOND-LINE LUNG CANCER View More
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (TROPION-Lung17) SECOND-LINE LUNG CANCER View More
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) BREAST CANCER View More
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) BREAST CANCER View More
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) BREAST CANCER View More
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant Plus a CDK4/6 Inhibitor, in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) BREAST CANCER View More
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+, HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT) BREAST CANCER View More
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) HEAD AND NECK CANCER View More
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma UROTHELIAL CANCER View More
Study of STP938 in Advanced Solid Tumours SOLID TUMORS View More
A Phase 1/1b Study of IAM1363 in HER2 Cancers SOLID TUMORS View More
Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) OBSERVATIONAL TRIALS View More
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers OBSERVATIONAL TRIALS View More
Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies OBSERVATIONAL TRIALS View More
Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study OBSERVATIONAL TRIALS View More
Trial NameCategoryTrial URL
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)FIRST LINE LUNG CANCERhttps://clinicaltrials.gov/study/NCT06119581
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsFIRST LINE LUNG CANCERhttps://clinicaltrials.gov/study/NCT05899608
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLCFIRST LINE LUNG CANCERhttps://clinicaltrials.gov/study/NCT06627647
Study of Olomorasib (LY3537982) in Combination with Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)FIRST LINE LUNG CANCERhttps://clinicaltrials.gov/study/NCT06890598
A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerSECOND-LINE LUNG CANCERhttps://clinicaltrials.gov/study/NCT06568939
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)SECOND-LINE LUNG CANCERhttps://clinicaltrials.gov/study/NCT06472245
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (TROPION-Lung17)SECOND-LINE LUNG CANCERhttps://clinicaltrials.gov/study/NCT07291037
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)BREAST CANCERhttps://clinicaltrials.gov/study/NCT05952557
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)BREAST CANCERhttps://clinicaltrials.gov/study/NCT06797635
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)BREAST CANCERhttps://clinicaltrials.gov/study/NCT06312176
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant Plus a CDK4/6 Inhibitor, in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)BREAST CANCERhttps://clinicaltrials.gov/study/NCT06065748
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+, HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)BREAST CANCERhttps://clinicaltrials.gov/study/NCT06492616
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)HEAD AND NECK CANCERhttps://clinicaltrials.gov/study/NCT06256588
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaUROTHELIAL CANCERhttps://clinicaltrials.gov/study/NCT07129993
Study of STP938 in Advanced Solid TumoursSOLID TUMORShttps://clinicaltrials.gov/study/NCT06297525
A Phase 1/1b Study of IAM1363 in HER2 CancersSOLID TUMORShttps://clinicaltrials.gov/study/NCT06253871
Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)OBSERVATIONAL TRIALShttps://clinicaltrials.gov/study/NCT06230185
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer BiomarkersOBSERVATIONAL TRIALShttps://clinicaltrials.gov/study/NCT06605404
Collection of Biological Specimens and Associated Health Information for Secondary Research in Future StudiesOBSERVATIONAL TRIALShttps://clinicaltrials.gov/study/NCT06369441
Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational StudyOBSERVATIONAL TRIALShttps://clinicaltrials.gov/study/NCT07124000

FAQ

We are currently offering trials for the following diagnoses: